Literature DB >> 24468718

Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures.

Foster Chen1, Zhong Wang1, Timothy Bhattacharyya2.   

Abstract

The radiographs of patients on long term bisphosphonates with atypical femur fractures demonstrate markedly thick cortices at the site of the fracture. We conducted a prospective clinical study to determine if cortical thickening is increased in long term bisphosphonate users. We recruited 43 patients who had taken bisphosphonates for more than 5 years. A group of 45 healthy volunteers and 12 patients recently diagnosed with osteoporosis served as controls. We measured the cortical thickening as the ratio of femoral cortical thickness to diameter of the femur, and looked for cortical beaking. No difference in the cortical thickness ratio was observed between long term bisphosphonate users and osteoporotic controls (0.53 vs. 0.54, p=0.659). No cases of cortical beaking were seen and no increase in thigh pain was observed. The power of the study was 95% to detect a 10% difference in cortical thickness ratio. We conclude that long term bisphosphonate use does not produce a generalized increase in subtrochanteric femoral cortical thickening in the majority of patients.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Atypical femur fracture; Osteoporosis

Mesh:

Substances:

Year:  2014        PMID: 24468718      PMCID: PMC4249765          DOI: 10.1016/j.bone.2014.01.011

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

2.  Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy.

Authors:  Renata La Rocca Vieira; Zehava Sadka Rosenberg; Mary B Allison; Shelly A Im; James Babb; Valerie Peck
Journal:  AJR Am J Roentgenol       Date:  2012-05       Impact factor: 3.959

3.  The effect of long-term alendronate treatment on cortical thickness of the proximal femur.

Authors:  Aasis Unnanuntana; Kashif Ashfaq; Quang V Ton; John P Kleimeyer; Joseph M Lane
Journal:  Clin Orthop Relat Res       Date:  2011-07-20       Impact factor: 4.176

4.  Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls.

Authors:  Jörg Schilcher; Veronika Koeppen; Jonas Ranstam; Ralf Skripitz; Karl Michaëlsson; Per Aspenberg
Journal:  Bone       Date:  2012-10-22       Impact factor: 4.398

Review 5.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

6.  Atypical fractures do not have a thicker cortex.

Authors:  V A Koeppen; J Schilcher; P Aspenberg
Journal:  Osteoporos Int       Date:  2012-10-18       Impact factor: 4.507

7.  A retrospective review of patients with atypical femoral fractures while on long-term bisphosphonates: including pertinent biochemical and imaging studies.

Authors:  Lisa H Markman; Mary B Allison; Zehava S Rosenberg; Renata L Vieira; James S Babb; Nirmal C Tejwani; Shelly A Im; Valerie Peck
Journal:  Endocr Pract       Date:  2013 May-Jun       Impact factor: 3.443

8.  Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy.

Authors:  M B Allison; L Markman; Z Rosenberg; R L Vieira; J Babb; N Tejwani; V Peck
Journal:  Bone       Date:  2013-04-05       Impact factor: 4.398

9.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

  9 in total
  8 in total

1.  Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.

Authors:  Yoichi Iizuka; Rumi Takechi; Haku Iizuka; Takuya Omodaka; Kenji Takagishi
Journal:  Skeletal Radiol       Date:  2016-07-11       Impact factor: 2.199

2.  The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; Y Wada; T Nakatsue; S Iguchi; J Fujisawa; J J Kazama; T Kuroda; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2015-10-30       Impact factor: 4.507

3.  Which AO/OTA 31-A2 pertrochanteric fractures can be treated with a dynamic hip screw without developing a lateral wall fracture? A CT-based study.

Authors:  Gaurav Sharma; Ravijot Singh; Kiran Kumar Gn; Vaibhav Jain; Ankit Gupta; Shivanand Gamanagatti; Kamran Farooque; Vijay Sharma
Journal:  Int Orthop       Date:  2015-07-04       Impact factor: 3.075

4.  Factors associated with atypical femoral fracture.

Authors:  Dam Kim; Yoon-Kyoung Sung; Soo-Kyung Cho; Minkyung Han; Yee-Suk Kim
Journal:  Rheumatol Int       Date:  2015-07-23       Impact factor: 2.631

5.  Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.

Authors:  Rahel Meinen; Inna Galli-Lysak; Peter M Villiger; Daniel Aeberli
Journal:  BMC Musculoskelet Disord       Date:  2016-08-05       Impact factor: 2.362

6.  Atypical Femoral Shaft Fractures in Female Bisphosphonate Users Were Associated with an Increased Anterolateral Femoral Bow and a Thicker Lateral Cortex: A Case-Control Study.

Authors:  Seung Pil Jang; Ingwon Yeo; Sang-Yeon So; Keunbyuel Kim; Young-Wan Moon; Youn-Soo Park; Seung-Jae Lim
Journal:  Biomed Res Int       Date:  2017-03-28       Impact factor: 3.411

7.  Skeletal Site-Specific Response of Jawbones and Long Bones to Surgical Interventions in Rats Treated with Zoledronic Acid.

Authors:  Jing Yi Wang; Lei Huo; Ru Qing Yu; Nian Jing Rao; Weijia William Lu; Li Wu Zheng
Journal:  Biomed Res Int       Date:  2019-12-18       Impact factor: 3.411

8.  Hypophosphatasia and the risk of atypical femur fractures: a case-control study.

Authors:  Timothy Bhattacharyya; Smita Jha; Hongying Wang; Daniel L Kastner; Elaine F Remmers
Journal:  BMC Musculoskelet Disord       Date:  2016-08-09       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.